Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice ; volume:13 ; number:1 ; day:4 ; month:2 ; year:2011 ; pages:1-11 ; date:2.2011
Breast cancer research ; 13, Heft 1 (4.2.2011), 1-11, 2.2011
- Urheber
-
Ladjemi, Maha Z.
- Beteiligte Personen und Organisationen
-
Chardes, Thierry
Corgnac, Stéphanie
Garambois, Véronique
Morisseau, Sebastien
Robert, Bruno
Bascoul-Mollevi, Caroline
Ait Arsa, Imade
Jacot, William
Pouget, Jean-Pierre
Pèlegrin, André
Navarro-Teulon, Isabelle
SpringerLink (Online service)
- DOI
-
10.1186/bcr2826
- URN
-
urn:nbn:de:1111-2016032411433
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ladjemi, Maha Z.
- Chardes, Thierry
- Corgnac, Stéphanie
- Garambois, Véronique
- Morisseau, Sebastien
- Robert, Bruno
- Bascoul-Mollevi, Caroline
- Ait Arsa, Imade
- Jacot, William
- Pouget, Jean-Pierre
- Pèlegrin, André
- Navarro-Teulon, Isabelle
- SpringerLink (Online service)
Ähnliche Objekte (12)
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
Anti‐HER2 Super Stealth Immunoliposomes for Targeted‐Chemotherapy
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
Anti‐HER2 Super Stealth Immunoliposomes for Targeted‐Chemotherapy
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells